Portal de Periódicos da CAPES

Effects of Oxandrolone on Outcome Measures in the Severely Burned: A Multicenter Prospective Randomized Double-Blind Trial

2006; Oxford University Press; Volume: 27; Issue: 2 Linguagem: Inglês

10.1097/01.bcr.0000202620.55751.4f

1559-0488

Steven E. Wolf, Linda S. Edelman, Nathan A. Kemalyan, Lorraine Donison, James M. Cross, Marcia Underwood, Robert Spence, Dene Noppenberger, Tina L. Palmieri, David G. Greenhalgh, MaryBeth Lawless, David W. Voigt, Paul A. Edwards, Petra Warner, Richard J. Kagan, Susan M. Hatfield, James C. Jeng, Daria Crean, John L. Hunt, Gary F. Purdue, Agnes Burris, Bruce A. Cairns, M. V. Kessler, Robert Klein, Rose Baker, Charles J. Yowler, Wendy Tutulo, Kevin N Foster, Daniel M. Caruso, Brian Hildebrand, Wesley Benjamin, Cynthia Villarreal‐Garza, Arthur P. Sanford, Jeffrey R. Saffle,

Wound Healing and Treatments

Severe burns induce pathophysiologic problems, among them catabolism of lean mass, leading to protracted hospitalization and prolonged recovery. Oxandrolone is an anabolic agent shown to decrease lean mass catabolism and improve wound healing in the severely burned patients. We enrolled 81 adult subjects with burns 20% to 60% TBSA in a multicenter trial testing the effects of oxandrolone on length of hospital stay. Subjects were randomized between oxandrolone 10 mg every 12 hours or placebo. The study was stopped halfway through projected enrollment because of a significant difference between groups found on planned interim analysis. We found that length of stay was shorter in the oxandrolone group (31.6 ± 3.1 days) than placebo (43.3 ± 5.3 days; P < .05). This difference strengthened when deaths were excluded and hospital stay was indexed to burn size (1.24 ± 0.15 days/% TBSA burned vs 0.87 ± 0.05 days/% TBSA burned, P < .05). We conclude that treatment using oxandrolone should be considered for use in the severely burned while hepatic transaminases are monitored.